Cantargia AB (publ) (CANTA) Earnings Call Transcripts

Cantargia AB (publ)'s Latest Earnings Call - June 22, 2026

In the earnings call for Cantargia AB (CANTA:SE) for Q2 2026, the focus was on the development of nadunolimab, an anti-IL-1RAP antibody, as a treatment for pancreatic ductal adenocarcinoma (PDAC). The company did not provide specific revenue or earnings figures in the call, but emphasized the potential of nadunolimab to address the dense inflammatory stroma in PDAC, which is a significant barrier to effective treatment. Management highlighted ongoing and future clinical trials, including combinations with RAS inhibitors, which could significantly impact the treatment landscape. No changes to financial guidance were discussed.

Reported metrics

Guidance from management

Cantargia plans to initiate a Phase Ib/IIa study in late 2026 or early 2027, focusing on safety and exploratory endpoints. No financial guidance changes were mentioned.

What analysts pressed on

Analysts are concerned about the ability to demonstrate a clear biological effect in the upcoming trials without a control arm, and the challenge of overcoming resistance mechanisms in PDAC.

Main topics on the call

• Nadunolimab's Mechanism of Action — Nadunolimab targets the inflammatory stroma in PDAC, which is a major barrier to treatment. Dr. Datta noted, 'IL-1RAP is the common denominator between all of the receptors that receive inputs from IL-1 signaling.'
• Clinical Trial Developments — Cantargia plans to initiate a Phase Ib/IIa study combining nadunolimab with RAS inhibitors in Q4 2026 or Q1 2027. The primary focus will be on safety, tolerability, and exploratory endpoints.
• Strategic Positioning of Nadunolimab — Management is considering multiple paths for nadunolimab, including use in second-line settings with RAS inhibitors and in first-line settings to enhance efficacy and counteract resistance.
• Unmet Needs in PDAC Treatment — Dr. Hosein emphasized the need for new treatments due to the limited efficacy and high toxicity of current chemotherapy regimens, stating, 'I would have to put my satisfaction as very dissatisfied with the current availa...

Read the full Cantargia AB (publ) transcript (June 22, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 13 Cantargia AB (publ) earnings call transcripts on record, spanning August 22, 2023 to June 22, 2026. Based on this history, Cantargia AB (publ) reports quarterly. The most recent call on file is dated June 22, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

CANTA

Exchange

OM

Country

SE

Sector

Health Care

Industry

Biotechnology

Calls on record

13

First call

August 22, 2023

Most recent

June 22, 2026

Reporting cadence

quarterly